日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer

奥拉帕尼联合度伐利尤单抗治疗转移性去势抵抗性前列腺癌患者的II期研究

Li, Chennan; Madan, Ravi A; Lee, Min-Jung; Lee, Sunmin; Sato, Nahoko; Rastogi, Shraddha; Shrestha, Roshan; Aragon-Ching, Jeanny B; Goswami, Meghali; Donahue, Renee N; Cordes, Lisa M; Baj, Anna; Seo, Clara C Y; Terrigino, Nicholas T; Bright, John R; Hennigan, S Thomas; King, Isaiah M; Trostel, Shana Y; Fenimore, John M; Liu, Yi; Calzone, Kathleen A; Schlom, Jeffrey; Gulley, James L; Dahut, William L; Figg, William D; Sowalsky, Adam G; Lee, Jung-Min; Karzai, Fatima

The quadruple immunotherapy for colorectal cancer (QuICC) trial for mismatch repair-proficient metastatic colorectal cancer

针对错配修复功能正常的转移性结直肠癌的四重免疫疗法(QuICC)试验

Bracken-Clarke, Dara; Pastor, Danielle M; Marté, Jennifer L; Donahue, Renee N; Hodge, James W; Cordes, Lisa; Floudas, Charalampos S; Tschernia, Nicholas P; Karzai, Fatima; Brownell, Isaac; Turkbey, Evrim B; Soon-Shiong, Patrick; Schlom, Jeffrey; Gulley, James L; Maeng, Hoyoung M; Strauss, Julius; Redman, Jason M

A phase 2 study of GI-6207 in patients with recurrent medullary thyroid cancer

GI-6207治疗复发性甲状腺髓样癌患者的II期研究

Del Rivero, Jaydira; Donahue, Renee N; Marte, Jennifer L; Gramza, Ann; Bilusic, Marijo; Cordes, Lisa; Karzai, Fatima; Schlom, Jeffery; Gulley, James L; Madan, Ravi A

Long-Term Follow-Up of Neoadjuvant Enzalutamide Plus Androgen Deprivation Therapy in Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Feasibility Trial

新辅助恩扎卢胺联合雄激素剥夺疗法治疗局限性前列腺癌的长期随访:一项新辅助可行性试验的二次分析

Millan, Braden; Pramod, Nikhil; Blachman-Braun, Ruben; Saini, Jaskirat; Loebach, Lauren; Patel, Milan; Gurram, Sandeep; Turkbey, Baris; Karzai, Fatima; Pinto, Peter A

Integrative dual ctDNA 5mC/5hmC methylomics and clonal reconstruction infer tumor transcription and resistance phenotypes in metastatic prostate cancer

整合双重ctDNA 5mC/5hmC甲基化组学和克隆重建推断转移性前列腺癌的肿瘤转录和耐药表型

Li, Chennan; Baj, Anna; Seo, Clara C Y; Terrigino, Nicholas T; Bright, John R; Hennigan, S Thomas; King, Isaiah M; Wilkinson, Scott; Huang, Tzu-Ting; Trostel, Shana Y; Figg, William D; Dahut, William L; Takeda, David Y; Lee, Jung-Min; Karzai, Fatima; Sowalsky, Adam G

Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer.

阐明针对致命性前列腺癌的 MCL1 分子分层单药和联合治疗策略。

Jiménez-Vacas Juan M, Westaby Daniel, Figueiredo Ines, De Haven Brandon Alexis, Padilha Ana, Yuan Wei, Seed George, Bogdan Denisa, Gurel Bora, Bertan Claudia, Miranda Susana, Lambros Maryou, Montero-Hidalgo Antonio J, Coleman Ilsa, Yu Ivan Pak Lok, Buroni Lorenzo, Zeng Wanting, Neeb Antje J, Welti Jon, Rekowski Jan, Paravati Roberta, Gabel Florian, Pandell Nicole, Ferreira Ana, Crespo Mateus, Riisnaes Ruth, Das Souvik, Taylor Joe, Waldron Nick, Hobern Emily, Valenti Melanie, Ning Jian, Bernett Ilona, Liodaki Kate, Persse Thomas, Galipeau Patricia, Wilkinson Scott, Trostel Shana Y, Karzai Fatima, Chau Cindy H, Beatson Erica L, Zhang Xiaohu, Klumpp-Thomas Carleen, Varkaris Andreas, Luque Raul M, Swain Amanda, Raynaud Florence, Lack Nathan A, Thomas Craig J, Ha Gavin, Figg William D, Bezzi Marco, Sowalsky Adam G, Nelson Peter S, Carreira Suzanne, Balk Steven P, de Bono Johann S, Sharp Adam

Androgen deprivation-mediated activation of AKT is enhanced in prostate cancer with TMPRSS2:ERG fusion.

在具有 TMPRSS2:ERG 融合的前列腺癌中,雄激素剥夺介导的 AKT 激活增强。

Ma Fen, Chen Sen, Cecchi Luigi, Ersoy-Fazlioglu Betul, Russo Joshua W, Arai Seiji, Awad Seifeldin, Calagua Carla, Xie Fang, Poluben Larysa, Voznesensky Olga, Ku Anson T, Karzai Fatima, Cai Changmeng, Einstein David J, Ye Huihui, Yuan Xin, Toker Alex, Taplin Mary-Ellen, Sowalsky Adam G, Balk Steven P

Localized high-risk prostate cancer harbors an androgen receptor activity-low subpopulation susceptible to HER2 inhibition

局部高危前列腺癌中存在雄激素受体活性低的亚群,该亚群对HER2抑制剂敏感。

Scott Wilkinson ,Anson T Ku ,Rosina T Lis ,Isaiah M King ,Daniel Low ,Shana Y Trostel ,John R Bright ,Nicholas T Terrigino ,Anna Baj ,Emily R Summerbell ,Kayla E Heyward ,Sumeyra Kartal ,John M Fenimore ,Chennan Li ,Cassandra Singler ,BaoHan Vo ,Caroline S Jansen ,Huihui Ye ,Nichelle C Whitlock ,Stephanie A Harmon ,Nicole V Carrabba ,Rayann Atway ,Ross Lake ,David Y Takeda ,Haydn T Kissick ,Peter A Pinto ,Peter L Choyke ,Baris Turkbey ,William L Dahut ,Fatima Karzai ,Adam G Sowalsky

Programmed death-1 inhibition increases vaccine-induced T-cell infiltration in patients with prostate cancer.

程序性死亡受体1抑制剂可增加前列腺癌患者体内疫苗诱导的T细胞浸润

Lassoued Wiem, Madan Ravi A, Xue Elisabetta, Burnett Daniel, Canubas Kenneth D, Bailey Shania, Marté Jennifer L, Tsai Yo-Ting, Donahue Renee N, Turkbey Ismail Baris, Papanicolau-Sengo Antonios, Williams Moniquea, Hankin Amy, Manukyan Manuk, Manu Michell, Kang Zhigang, Pritchard Colin, Dahut William, Karzai Fatima, Schlom Jeffrey, Sater Sam, Pinto Peter, Gulley James L

Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009-2023)

癌症临床试验中受试者的性能状态资格要求和入组特征,最终获得美国食品药品监督管理局 (FDA) 的药物批准(2009-2023 年)

Iannantuono, Giovanni Maria; Floudas, Charalampos S; Filetti, Marco; Giovagnoli, Tommaso; Sganga, Stefano; Vitale, Antonio; Chandran, Elias; Lombardi, Pasquale; Rosenfeld, Roberto; Giudice, Elena; Xue, Elisabetta; Rapisarda, Elvira; Troisi, Paola; Apolo, Andrea B; Karzai, Fatima; Bria, Emilio; Gulley, James L; Daniele, Gennaro